THMO - ThermoGenesis Holdings

Ridentro a 0.62...lumedi trimestrale...market cap ridicolo..
 
Thermogenesis Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview

* Thermogenesis Holdings Inc is expected to show a rise in quarterly revenue when it reports results on March 28.

* The Rancho Cordova California-based company is expected to report a 73.3% increase in revenue to $3.374 million from $1.95 million a year ago, according to the estimate from one analyst, based on Refinitiv data.

* ​Refinitiv's mean analyst estimate for Thermogenesis Holdings Inc is for a loss of 6 cents per share. For the same quarter last year, the company reported a loss of 24 cents per share.

* The one available analyst rating on the shares is "buy".

* The mean earnings estimate of analysts was unchanged in the last three months. ​

This summary was machine generated March 25 at 22:20 GMT. All figures in US dollars unless otherwise stated.
 
Ridentro 0.28 ...non ha molto cash ma market cap di 3.5 milioni si tenta
 
visto l'entrata del grande mastro medio a 0.28 speriamo.. le ho un po alte a 0.70
 
Ieri quasi 8 milioni di azioni e titolo fermo......mmmmm mi sa di distribuzione...non un bel segnale vedrò oggi che fare
 
Fuori...troppi movimenti strani...magari poi sale .ma non mi fido
 
Dec 21 (Reuters) - Thermogenesis Holdings Inc (THMO.O):
* THERMOGENESIS ANNOUNCES 1-FOR-45 REVERSE STOCK SPLIT
* ANNOUNCED A 1-FOR-45 REVERSE STOCK SPLIT OF ITS OUTSTANDING COMMON STOCK, EFFECTIVE DECEMBER 22, 2022
 
prevedo valanghe di r/s sulle bio ciofeche nelle prossime settimane/mesi
 
UZZ-Thermogenesis rises on plans to roll out manufacturing facility for lease
Oggi 16:47 - RSF
March 15 (Reuters) - ** Shares of cell-based medical device company Thermogenesis Holding (THMO.O) nearly double to $4.16
** THMO says it will roll out a facility in Sacramento comprising 12 class-7 ReadyStart cGMP Suites available for lease later this year by early-stage life science and cell gene therapy cos
** If fully occupied, facility is anticipated to generate an estimated $10-16 mln in annual revenue
** The roll-out is part of co's previously announced plan to transform to a contract development and manufacturing organization in cell-gene therapy field
** Facility is expected to be available for customers in second or third quarter of this year
** YTD THMO was up 27.5%
 
Indietro